UBS Group’s Northwest Biotherapeutics, Inc. NWBOW Stock Holding History

UBS Group’s Portfolio NWBOW Stock Details NWBOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,508	Closed	-$1K	–	8434
2016 Q3	$1K	Buy	+1,508	New	+$432	﹤0.01%	7600
2016 Q1	–	Sell	-162	Closed	–	–	8829
2015 Q4	$0	Sell	162 -801	-83%	-$2.33K	﹤0.01%	8968
2015 Q3	$3K	Buy	+963	New	+$5.57K	﹤0.01%	8028

Other funds holding NWBOW

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

UBS Group's NWBOW Position: Q4 2016 in Review

UBS Group sold out of Northwest Biotherapeutics, Inc. (NWBOW) in Q4 2016, closing a stake of 1,508 shares — an estimated $1K sold.

UBS Group first reported a position in NWBOW in Q3 2015 and held it in 3 quarters. The position peaked at $3K in Q3 2015. 1 fund tracked by Wall St. Rank holds NWBOW as of Q4 2016.

UBS Group reported no remaining Northwest Biotherapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
UBS Group sold 1,508 Northwest Biotherapeutics, Inc. shares in Q4 2016, an estimated $1K.
UBS Group first reported a position in Northwest Biotherapeutics, Inc. in Q3 2015 and held it in 3 quarters.
UBS Group's Northwest Biotherapeutics, Inc. position peaked at $3K in Q3 2015.
1 fund tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.